Evaluation of a hybrid telehealth care pathway for patients with axial spondyloarthritis including self-sampling at home: results of a longitudinal proof-of-concept mixed-methods study (TeleSpactive).
Labinsky HannahSusann MayKatharina BoySophie von RohrManuel GrahammerSebastian KuhnJessica RojasEkaterina VogtMartin HeinzeLarissa Valor-MéndezMuehlensiepen FelixJohannes KnitzaPublished in: Rheumatology international (2024)
Patients with axial spondyloarthritis (axSpA) require close monitoring to achieve the goal of sustained disease remission. Telehealth can facilitate continuous care while relieving scarce healthcare resources. In a mixed-methods proof-of-concept study, we investigated a hybrid telehealth care axSpA pathway in patients with stable disease over 6 months. Patients used a medical app to document disease activity (BASDAI and PtGA bi-weekly, flare questionnaire weekly). To enable a remote ASDAS-CRP (TELE-ASDAS-CRP), patients used a capillary self-sampling device at home. Monitoring results were discussed and a decision was reached via shared decision-making whether a pre-planned 3-month on-site appointment (T3) was necessary. Ten patients completed the study, and eight patients also completed additional telephone interviews. Questionnaire adherence was high; BASDAI (82.3%), flares (74.8%) and all patients successfully completed the TELE-ASDAS-CRP for the T3 evaluation. At T3, 9/10 patients were in remission or low disease activity and all patients declined the offer of an optional T3 on-site appointment. Patient acceptance of all study components was high with a net promoter score (NPS) of +50% (mean NPS 8.8 ± 1.5) for self-sampling, +70% (mean NPS 9.0 ± 1.6) for the electronic questionnaires and +90% for the T3 teleconsultation (mean NPS 9.7 ± 0.6). In interviews, patients reported benefits such as a better overview of their condition, ease of use of telehealth tools, greater autonomy, and, most importantly, travel time savings. To our knowledge, this is the first study to investigate a hybrid approach to follow-up axSpA patients including self-sampling. The positive results observed in this scalable proof-of-concept study warrant a larger confirmatory study.
Keyphrases
- end stage renal disease
- healthcare
- newly diagnosed
- ejection fraction
- chronic kidney disease
- disease activity
- peritoneal dialysis
- prognostic factors
- clinical trial
- randomized controlled trial
- systemic lupus erythematosus
- dna methylation
- skeletal muscle
- metabolic syndrome
- palliative care
- case report
- patient reported
- quality improvement
- chronic pain
- transcription factor
- pain management
- cross sectional
- glycemic control
- double blind
- health insurance